N-[5-(5-amino-6-methylpyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[5-(5-amino-6-methylpyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide
• 化学式: C₁₂H₁₄N₄OS
• 分子量: 262.335
• InChiKey: PHNJJAJQFILLLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[5-(5-amino-6-methylpyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide 在 盐酸 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 吡啶 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成
  参考文献：
  名称：

  Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor

  摘要：

  PI3K delta, which is mainly expressed in leukocytes, plays a critical role in B-cell receptor mediated signaling pathway and has been extensively studied as a drug discovery target for B cell malignances such as AML, CLL etc. In this manuscript, we report the discovery, SAR optimization and pharmacological evaluation of a novel series of aminothiazole-pyridine containing PI3K delta inhibitors. Among them compound 151 (CHMFL-PI3K delta-317) displays an IC50 of 6 nM against PI3K delta in the ADP-Glo biochemical assays. It also exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms. In addition, in the cellular context, 15i can selectively and potently inhibit PI3K delta mediated phosphorylation of Akt T308 but not PI3K delta, beta, gamma mediated Akt phosphorylation. 15i also exhibits an excellent selectivity profile in the protein kinases including 468 kinases/mutants at the concentration of 1 mu M. 15i has acceptable pharmacokinetic properties and can dose-dependently inhibit the tumor growth of AML cell line MOLM14 inoculated xenograft mouse model. The high selectivity and potency makes 15i a potential valuable addition to the current PI3K delta armory. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.07.036
• 作为产物：
  描述：

  N-(5-(5-amino-6-chloropyridin-3-yl)-4-methylthiazol-2-yl)acetamide 、 三甲氧基环硼氧烷 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 caesium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 0.75h， 生成 N-[5-(5-amino-6-methylpyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide
  参考文献：
  名称：

  WO2006/51270

  摘要：

  公开号：

文献信息

• 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors
  申请人：Bengtsson Malena

  公开号：US20080132502A1

  公开（公告）日：2008-06-05

  The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R 1 , R 2 and R 3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

  本发明提供式(I)的噻唑衍生物或其药学上可接受的盐，其中环A、R1、R2和R3如说明书中所定义；一种制备它们的方法；含有它们的制药组合物；以及它们在治疗中的用途，例如用于治疗由PI3K酶和/或mTOR激酶介导的疾病。
• 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1841763B1

  公开（公告）日：2010-06-30
• US7868188B2
  申请人：——

  公开号：US7868188B2

  公开（公告）日：2011-01-11
• WO2006/51270
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor
  作者：Xiaofei Liang、Feng Li、Cheng Chen、Zongru Jiang、Aoli Wang、Xiaochuan Liu、Juan Ge、Zhenquan Hu、Kailin Yu、Wenliang Wang、Fengming Zou、Qingwang Liu、Beilei Wang、Li Wang、Shanchun Zhang、Yuxin Wang、Qingsong Liu、Jing Liu

  DOI：10.1016/j.ejmech.2018.07.036

  日期：2018.8

  PI3K delta, which is mainly expressed in leukocytes, plays a critical role in B-cell receptor mediated signaling pathway and has been extensively studied as a drug discovery target for B cell malignances such as AML, CLL etc. In this manuscript, we report the discovery, SAR optimization and pharmacological evaluation of a novel series of aminothiazole-pyridine containing PI3K delta inhibitors. Among them compound 151 (CHMFL-PI3K delta-317) displays an IC50 of 6 nM against PI3K delta in the ADP-Glo biochemical assays. It also exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms. In addition, in the cellular context, 15i can selectively and potently inhibit PI3K delta mediated phosphorylation of Akt T308 but not PI3K delta, beta, gamma mediated Akt phosphorylation. 15i also exhibits an excellent selectivity profile in the protein kinases including 468 kinases/mutants at the concentration of 1 mu M. 15i has acceptable pharmacokinetic properties and can dose-dependently inhibit the tumor growth of AML cell line MOLM14 inoculated xenograft mouse model. The high selectivity and potency makes 15i a potential valuable addition to the current PI3K delta armory. (C) 2018 Elsevier Masson SAS. All rights reserved.